Advanced in Leukemia

Overview

Jessica Heath is a Pediatric Hematologist Oncology specialist and a Hematologist in Burlington, Vermont. Dr. Heath and is rated as an Advanced provider by MediFind in the treatment of Leukemia. Her top areas of expertise are Leukemia, Histiocytosis, Reticulohistiocytoma, Hepatoblastoma, and Bone Marrow Aspiration. Dr. Heath is currently accepting new patients.

Her clinical research consists of co-authoring 23 peer reviewed articles and participating in 33 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 13 articles and participated in 6 clinical trials in the study of Leukemia.

Specialties
Pediatric Hematology Oncology
Hematology
Licenses
Pediatric Hematology-Oncology in NC
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

111 Colchester Ave, Uvm Medical Center - Children's, Pedi-hem/onc, Burlington, VT 05401
802-847-2850

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


33 Clinical Trials

A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
View 32 Less Clinical Trials
Similar Doctors
Expertise in
54
conditions
Hematology Oncology | Hematology | Oncology
Expertise in
54
conditions
Hematology Oncology | Hematology | Oncology
75 Beekman St, 
Plattsburgh, NY 
 (20.4 mi)
Experience:
21+ years
Languages Spoken:
English

Jan Duus is a Hematologist Oncology specialist and a Hematologist in Plattsburgh, New York. Dr. Duus has been practicing medicine for over 21 years and is rated as a Distinguished provider by MediFind in the treatment of Leukemia. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Non-Hodgkin Lymphoma, and Bone Marrow Aspiration.

Expertise in
52
conditions
Hematology | Oncology
Expertise in
52
conditions
Hematology | Oncology

University Of Vermont Medical Center Inc

1 S Prospect St, 
Burlington, VT 
 (0.4 mi)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Julian Sprague is a Hematologist and an Oncologist in Burlington, Vermont. Dr. Sprague and is rated as a Distinguished provider by MediFind in the treatment of Leukemia. His top areas of expertise are Autoimmune Hemolytic Anemia, Large-Cell Immunoblastic Lymphoma, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sprague is currently accepting new patients.

Expertise in
6
conditions
Hematology Oncology | Hematology | Oncology
Expertise in
6
conditions
Hematology Oncology | Hematology | Oncology

University Of Vermont Medical Center Inc

111 Colchester Ave, 
Burlington, VT 
Experience:
14+ years
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Diego Adrianzen-Herrera is a Hematologist Oncology specialist and a Hematologist in Burlington, Vermont. Dr. Adrianzen-Herrera has been practicing medicine for over 14 years and is rated as a Distinguished provider by MediFind in the treatment of Leukemia. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Adrianzen-Herrera is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile